Dyne Therapeutics prices upsized $350M public offering at $18.44/share

Dyne Therapeutics, Inc.

Priced 18,980,478 shares at $18.44/share; gross proceeds $350M.
Underwriters granted 30-day option for additional 2,847,071 shares.
Net proceeds estimated at ~$328.5M ($377.9M if option exercised).
Also borrowed $50M second tranche under Hercules Loan Agreement.
Cash runway extended into Q1 2028 with combined resources.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Dyne Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters valued at approximately $328.5 million (effective 2025-12-09).

Action: entry
Agreement: underwriting
Counterparty: Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters
Value: approximately $328.5 million
Effective: 2025-12-09

Exact text from the filing

On December 9, 2025, Dyne Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 18,980,478 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-314249

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.